SCHEMBL4315427

SCHEMBL4315427

CC(C)C[C@H](NC(=O)OC(C)(C)C)C(=O)N([C@H]1CC[C@@H](C)NC[C@@H]1O)S(=O)(=O)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.40
MMP13 P45452 2/20 0.38
CCR5 P51681 1/20 0.38
REN P00797 3/20 0.37
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
PLA2G1B P04054 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
XBP1 P17861 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ATG4B Q9Y4P1 1/20 0.36
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
PSEN1 P49768 2/20 0.35
PSEN2 P49810 2/20 0.35
APH1B Q8WW43 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4312508 1.00 MAPK1 (0.40) MAPK1MMP13CCR5RENALDH1A1
SCHEMBL4768354 0.89 CTSB (0.34) MMP13ALDH1A1HTTCTSLCTSB
SCHEMBL6213890 0.89 CTSB (0.34) MMP13ALDH1A1HTTCTSLCTSB
SCHEMBL4318514 0.88 MAPK1 (0.36) MAPK1RENALDH1A1KDM4EPLA2G1B
SCHEMBL4212772 0.79 CTSS (0.35) MAPK1MMP13ALDH1A1CTSLCTSB
SCHEMBL3955653 0.78 CTSL (0.36) MAPK1CTSLCTSBCTSSCTSK
SCHEMBL3955650 0.78 CTSL (0.36) MAPK1CTSLCTSBCTSSCTSK
SCHEMBL6214152 0.77 CTSK (0.37) MAPK1ALDH1A1KDM4ECTSLCTSB
SCHEMBL5971691 0.75 MAPK1 (0.36) MAPK1RENALDH1A1KDM4EPLA2G1B
SCHEMBL7254317 0.74 MAPK1 (0.35) MAPK1RENALDH1A1KDM4EPLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060194787-A1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2006-08-31 US claimed
US-20040044201-A1 Protease inhibitors GLAXOSMITHKLINE LLC 2004-03-04 US claimed
US-7563784-B2 Protease inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-07-21 US disclosed
US-20060194787-A1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2006-08-31 US disclosed
US-7071184-B2 Protease inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2006-07-04 US disclosed
US-20040044201-A1 Protease inhibitors GLAXOSMITHKLINE LLC 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194787-A1 Protease inhibitors CTSK, CTSL, CTSZ MAPK1 2421/4885MMP13 6/4885CCR5 976/4885
US-20040044201-A1 Protease inhibitors CTSK, CTSE, CTSZ MAPK1 2113/4885MMP13 4/4885CCR5 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.